Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

Fig. 1

Flow diagram of the approach to identify and test Col10A1 in ER+/HER2+ breast tumors. From 538 patients, 74 ER+/HER2+ breast tumors were selected for analysis. 11 ER+/HER2+ tumors were selected for expression profiling using Affymetrix HTA 2.0 microarrays. After qPCR verification, we evaluated the level of colXα1 protein in primary tumors before NAC using immunohistochemistry to test the expression of colXα1 protein levels in 50 ER+/HER2+ breast tumors with available tissue

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us